Processing

Please wait...

Settings

Settings

1. NZ290911 - Hypolipidemic 1,4-benzothiazepine-1,1-dioxides

Office New Zealand
Application Number 290911
Application Date 09.08.1995
Publication Number 290911
Publication Date 28.07.1998
Grant Number
Grant Date 16.11.1998
Publication Kind B
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
513
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
281
Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
02
Seven-membered rings
04
having the hetero atoms in positions 1 and 4
08
condensed with carbocyclic rings or ring systems
10
condensed with one six-membered ring
A61K 31/55
C07D 513/04
C07D 417/04
C07D 281/10
CPC
A61K 31/554
C07D 281/10
C07D 513/04
C07F 9/6536
Applicants THE WELLCOME FOUNDATION LIMITED
Inventors Brieaddy, Lawrence Edward
Agents AJ PARK
Priority Data 94 288527 10.08.1994 US
Title
(EN) Hypolipidemic 1,4-benzothiazepine-1,1-dioxides
Abstract
(EN)
The specification relates to hypolipidemic compounds of formula (I) wherein R1 is a straight chained C1-6 alkyl group; R2 is a straight chained C1-6 alkyl group; R3 is H or a group OR11 in which R11 is H, optionally substituted C1-6 alkyl or a C1-6 alkylcarbonyl group; R4 is an unsubstituted phenyl; R5 is H; R6 and R8 are independently selected from H, C1-4 alkyl optionally substituted by fluorine, C1-4 alkoxy, halogen or hydroxy; R7 is selected from OR15, S(O)nR15, OCOR15, OCF3, OCN, SCN, CHO, OCH2OR15, OCH=CHR15, O(CH2CH2O)nR15, O(CH2)PSO3R15, O(CH2)PNR12R13 and O(CH2)PN+R12R13R14 wherein: p is an integer from 1-4; n is an integer from 0-3; and R12, R13, R14 and R15 are independently selected from H and optionally substituted C1-6 alkyl; R9 and R10 are the same or different and each is H or C1-6 alkyl. The compounds when prepared as pharmaceutical compositions are useful in medicines, particularly for the prophylaxis and treatment of hypolipidemic conditions, such as atherosclerosis...